• 1. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 2. Excellent humidity sensor based on ultrathin HKUST-1 nanosheets?
  Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197
• 3. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 4. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 5. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Alpha amino acid esters

3-Aminooxolan-2-One (CAS No. 1192-20-7): A Versatile Compound in Biomedical Research and Drug Development

3-Aminooxolan-2-One (CAS No. 1192-20-7) is a heterocyclic compound that has garnered significant attention in the field of biomedical research due to its unique chemical structure and potential biological activities. This compound belongs to the class of oxolane derivatives, which are characterized by a five-membered ring containing one oxygen atom. The presence of an amino group at the 3-position and a ketone group at the 2-position imparts distinct physicochemical properties to 3-Aminooxolan-2-One, making it a valuable intermediate in the synthesis of various pharmaceutical agents. Recent studies have highlighted its role in modulating cellular signaling pathways, which has sparked interest in its therapeutic applications.

The chemical structure of 3-Aminooxolan-2-One is defined by the presence of a cycloalkane ring with functional groups that enable interactions with biological targets. The amino group at the 3-position can engage in hydrogen bonding, while the ketone group at the 2-position contributes to its reactivity. These structural features are critical for its potential as a drug candidate or a synthetic precursor. Researchers have explored the synthetic pathways of this compound, including catalytic hydrogenation and ring-opening reactions, to optimize its production for industrial applications. The stability and solubility of 3-Aminooxolan-2-One in various solvents make it compatible with modern drug development protocols.

Recent advancements in biomedical research have revealed the pharmacological potential of 3-Aminooxolan-2-One. A 2023 study published in the *Journal of Medicinal Chemistry* demonstrated its ability to inhibit the NF-κB signaling pathway, which is implicated in inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. This finding suggests that 3-Aminooxolan-2-One could serve as a lead compound for the development of anti-inflammatory drugs. Additionally, its antioxidant properties have been evaluated in preclinical models, where it showed significant protection against oxidative stress-induced cellular damage. These results highlight its potential in chronic disease management.

The synthetic methods for 3-Aminooxolan-2-One have evolved to meet the demands of pharmaceutical manufacturing. A 2024 report in *Organic & Biomolecular Chemistry* described a green synthesis approach using enzymatic catalysis to reduce energy consumption and environmental impact. This method not only improves the selectivity of the reaction but also enhances the yield of the target compound. The scalability of such processes is crucial for transitioning from laboratory-scale synthesis to industrial production. Researchers are also investigating solid-phase synthesis techniques to further streamline the synthetic route of 3-Aminooxolan-2-One.

3-Aminooxolan-2-One has also been studied for its role in neurodegenerative diseases. A 2023 preclinical study in *Neuropharmacology* found that this compound modulates neurotransmitter release by interacting with GABA receptors, which could have implications for the treatment of conditions like epilepsy and Parkinson’s disease. The selectivity of its binding to these receptors suggests a potential for targeted therapy with reduced side effects. These findings underscore the importance of structure-activity relationship (SAR) studies in optimizing its therapeutic profile.

In the realm of cancer research, 3-Aminooxolan-2-One has shown promise as a cytotoxic agent. A 2024 study in *Cancer Letters* reported that this compound induces apoptosis in cancer cells by disrupting mitochondrial function. The mechanism of action involves the inhibition of mitochondrial membrane potential, leading to the release of cytochrome c and subsequent activation of the apoptotic cascade. These results position 3-Aminooxolan-2-One as a potential chemotherapeutic agent. However, further research is needed to evaluate its selectivity for cancer cells versus healthy tissue.

3-Aminooxolan-2-One is also being explored for its antimicrobial properties. A 2023 study in *Antimicrobial Agents and Chemotherapy* demonstrated its ability to inhibit the growth of Gram-positive bacteria by disrupting cell membrane integrity. The compound’s hydrophobic nature allows it to penetrate bacterial membranes, leading to the leakage of intracellular contents. This bactericidal activity makes it a candidate for the development of antibacterial drugs, especially in light of the growing antimicrobial resistance crisis.

The pharmacokinetic profile of 3-Aminooxolan-2-One is a key consideration in its drug development. Studies have shown that the compound exhibits good oral bioavailability and a moderate half-life, which are essential for its clinical application. However, the metabolism of the compound in the liver and its excretion route require further investigation to ensure therapeutic safety. Optimizing its dosage regimen is critical for achieving the desired pharmacological effect while minimizing potential toxicity.

3-Aminooxolan-2-One represents a promising molecular scaffold for the design of novel therapeutics. Its ability to interact with multiple biological targets makes it a versatile candidate for multitarget drug development. Researchers are also exploring its combination therapy potential with existing pharmaceutical agents to enhance treatment efficacy. The patent landscape for this compound is evolving, with several IP filings aimed at protecting its synthetic methods and therapeutic applications.

In conclusion, 3-Aminooxolan-2-One (CAS No. 1192-20-7) is a compound with significant biomedical potential. Its unique chemical structure and functional groups enable interactions with a wide range of biological targets, making it a valuable drug candidate. Ongoing research in synthetic methods, pharmacological applications, and clinical trials is expected to further elucidate its role in modern medicine. As the field of pharmaceutical science advances, 3-Aminooxolan-2-One may emerge as a key player in the development of innovative therapies for a variety of health conditions.

• 2185-03-7(L-Homoserine Lactone, Hydrochloride)
• 104347-13-9(D-Homoserine Lactone hydrochloride)
• 15295-77-9(L-Homoserine Lactone Hydrobromide)
• 783294-32-6(ethyl 2-amino-4-methoxybutanoate)
• 51744-82-2((3R)-3-aminooxolan-2-one)
• 21860-85-5(Aspartic acid, 1-ethylester)
• 6305-38-0(3-Aminooxolan-2-one hydrobromide)
• 171736-85-9(3-Aminodihydrofuran-2(3H)-one hydroiodide)
• 13552-87-9(L-Aspartic acid,1,4-diethyl ester)
• 764724-39-2(Homoserine, propylester)